These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 668145)

  • 21. Erythrocyte nucleotides from control and lead-treated rabbits.
    Swanson MS; Angle CR; Stohs SJ; Rovang KS
    Res Commun Chem Pathol Pharmacol; 1980 Feb; 27(2):353-61. PubMed ID: 6245437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erythrocyte pyrimidine 5'-nucleotidase activity in workers exposed to lead, mercury or cadmium.
    Mohammed-Brahim B; Buchet JP; Lauwerys R
    Int Arch Occup Environ Health; 1985; 55(3):247-52. PubMed ID: 2987134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A radioassay for pyrimidine-5'-nucleotidase activity.
    Buc H; Kaplan JC
    Clin Chim Acta; 1978 Apr; 85(2):193-6. PubMed ID: 647979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Electrophoretic and kinetic studies of human erythrocytes deficient in pyrimidine 5'-nucleotidase.
    Rosa R; Rochant H; Dreyfus B; Valentin C; Rosa J
    Hum Genet; 1977 Sep; 38(2):209-15. PubMed ID: 908567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erythrocyte arginase, pyrimidine 5'-nucleotidase (P5N), and deoxypyrimidine 5'-nucleotidase (dP5N) as indices of lead exposure.
    Cook LR; Angle CR; Stohs SJ
    Br J Ind Med; 1986 Jun; 43(6):387-90. PubMed ID: 3013277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Normal pyrimidine 5'-nucleotidase activity level of Japanese subjects and a significance as a marker for low concentration of lead in blood (author's transl)].
    Sato Y; Sasaki T; Taniguchi N; Saito K
    Nihon Eiseigaku Zasshi; 1981 Jun; 36(2):518-25. PubMed ID: 6273619
    [No Abstract]   [Full Text] [Related]  

  • 27. [Relationship between activity of erythrocyte pyrimidine 5'-nucleotidase (P5N) and concentration of magnesium or zinc in blood in workers exposed to lead].
    Ichiba M; Tomokuni K
    Sangyo Igaku; 1988 Sep; 30(5):408-9. PubMed ID: 2849695
    [No Abstract]   [Full Text] [Related]  

  • 28. An improved method for the determination of human erythrocyte pyrimidine 5'-nucleotidase activity.
    Ellims PH; Bailey L; Van der Weyden MB
    Clin Chim Acta; 1978 Aug; 88(1):99-103. PubMed ID: 679498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Purification and properties of human erythrocyte pyrimidine 5'-nucleotidase.
    Torrance JD; Whittaker D; Beutler E
    Proc Natl Acad Sci U S A; 1977 Sep; 74(9):3701-4. PubMed ID: 20631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low level lead and inhibition of erythrocyte pyrimidine nucleotidase.
    Angle CR; McIntire MS
    Environ Res; 1978 Oct; 17(2):296-302. PubMed ID: 233817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Partial purification and zinc dependence of human red cell pyrimidine-5'-nucleotidase.
    Markin RS; Angle CR; Swanson MS; Stohs SJ
    Enzyme; 1983; 30(2):134-8. PubMed ID: 6311532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Red cell pyrimidine 5' nucleotidase deficiency: determination of nucleotidase activity and nucleotide content using HPLC.
    Adair CG; Elder GE; Lappin TR; Bridges JM; Nelson MG
    Clin Chim Acta; 1988 Jan; 171(1):75-83. PubMed ID: 2832101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of blood lead by HPLC assay of erythrocyte pyrimidine 5'-nucleotidase.
    Cook LR; Angle CR; Kubitschek CE; Stohs SJ
    J Anal Toxicol; 1987; 11(1):39-42. PubMed ID: 3029506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evaluation of initial results of treatment of lead poisoning with EDTA].
    Petkova V; Adjarov D; Pavlova S; Naydenova E; Kerimova M; Kuneva T
    Med Lav; 1994; 85(4):299-308. PubMed ID: 7808345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of activity of erythrocyte pyrimidine 5'-nucleotidase (P5N) in lead exposed workers: with focus on the effect on hemoglobin.
    Kim Y; Yoo CI; Lee CR; Lee JH; Lee H; Kim SR; Chang SH; Lee WJ; Hwang CH; Lee YH
    Ind Health; 2002 Jan; 40(1):23-7. PubMed ID: 11926511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Partial purification and properties of nicotinamide adenine dinucleotide synthetase from human erythrocytes: evidence that enzyme activity is a sensitive indicator of lead exposure.
    Zerez CR; Wong MD; Tanaka KR
    Blood; 1990 Apr; 75(7):1576-82. PubMed ID: 2107886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential effects of low-level lead exposure on the natural isozymes of erythrocyte 5'-nucleotidase.
    Paglia DE; Renner SW; Bhambhani K
    Clin Biochem; 1999 Apr; 32(3):193-9. PubMed ID: 10383080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HPLC analysis of erythrocyte pyrimidine-5'-nucleotidase inhibition by lead.
    Rocco RM; Smart JL; Brown DR; Blumberg JB
    Res Commun Chem Pathol Pharmacol; 1981 Oct; 34(1):127-36. PubMed ID: 6273981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A family with red cell pyrimidine 5'-nucleotidase deficiency.
    Ben-Bassat I; Brok-Simoni F; Kende G; Holtzmann F; Ramot B
    Blood; 1976 Jun; 47(6):919-22. PubMed ID: 1276472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abnormal erythrocyte pyrimidine nucleotides in uremic subjects.
    Angle CR; Swanson MS; Stohs SJ; Markin RS
    Nephron; 1985; 39(3):169-74. PubMed ID: 2983249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.